Duloxetine Capsule, Delayed Release
Product Images NDC 68180-296

This appears to be a graph displaying the proportion of patients with relapse over time (in days) after being randomized and treated with either a placebo or Duloxetine. The x-axis shows the time in days and the y-axis shows the proportion of patients. The graph suggests that patients treated with Duloxetine may have a lower rate of relapse compared to those treated with a placebo, but more context and information would be needed to draw any firm conclusions.*

The text provides a chart with different treatments and their corresponding percentage of patient improvement. It compares Duloxetine at 60mg and 20mg doses versus a placebo. The text also shows the percentage of improvement in pain from baseline.*

Percentage of patients who experienced improvement in pain relative to their baseline was evaluated. The treatments administered were Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo. Other information is not available in the provided text.*

The text provides a chart showing the percentage of patients who experienced improvement in pain from baseline using Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The chart shows varying levels of improvement starting from above 0% up to 100%.*

This is a chart that shows the percentage of patients who improved while taking Duloxetine, a medication typically used to treat depression and anxiety disorders. The chart breaks down the percentage of improvement for three different doses of Duloxetine (120mg twice daily, 60mg once daily, and 60mg once daily) as well as a placebo. The chart also includes a measure of percent improvement in pain from baseline.*

This is a graph showing the percentage of patients' improvement in pain from baseline, with the x-axis indicating the percent improvement and the y-axis indicating the number of patients. The graph includes data for patients given either placebo or Duloxetine 60/120 mg per day. However, there is no data available for the percentage of improvement as the has failed to capture the exact data.*

This is a graph that represents the percentage of patients improved through the use of Placebo and Duloxetine 60 mg. The X-axis displays different improvement ranges starting from 50 and going up to 100, and the Y-axis represents the percentage of patients improved. The graph shows that Duloxetine 60 mg had a higher percentage of patients improved compared to Placebo. The second line in the text is an indication of the percentage of pain improvement from Baseline (BOCF), but there is no context to interpret it.*

The text describes the percentage of patient improvement in a clinical trial, specifically in relation to pain relief. The chart shows a comparison between placebo and duloxetine (at doses of 60/120 mg), with the latter resulting in an 80% improvement rating. The chart also includes a horizontal axis representing percent improvement in pain from baseline.*

This is a medication guide for a drug with the National Drug Code (NDC) 68180-294-06. Each delayed-release capsule of this drug contains 22.4 mg of duloxetine hydrochloride USP, which is equivalent to 20 mg of duloxetine. The proper dosage is not provided, so patients must review the accompanying Delayed-release Capsules USP for information. The medication guide must be given to each patient by the pharmacist. The drug is manufactured by Lupin Limited, an Indian company, and the capsules come in a bottle that holds 30 capsules. The medication guide is available on the Lupin Limited website. It needs to be stored properly, between 15°-30°C (59°-86°F), and in a tightly closed container. It should be kept away from children.*

This is a description of medication called Duloxetine, manufactured by Lupin Pharmaceuticals, Inc. It comes in delayed-release capsules containing 67.3mg duloxetine hydrochloride, equivalent to 60mg duloxetine. The usual dosage instructions are not available in this text, but it is advised to see the accompanying prescribing information. The medication should be stored at a temperature of 25°C (77°F) and kept out of reach of children in a tightly closed container. It is only available in the United States and manufactured by Lupin Limited in Goa, India. The text also includes dosage and prescription information for pharmacists, and a code number for the medication.*